FIELD: medicine.
SUBSTANCE: what is offered is the use of monoclonal antibodies recognising the O-acetylated form of ganglioside GD2 and not recognising ganglioside GD2 for treating cancer characterised by O-acetylated GD2 expression, particularly neuroectodermal tumours, as well as the use of said antibody related to a toxic molecule, a drug or a second antibody for treating cancer characterised by O-acetylated GD2 expression.
EFFECT: use of the invention can find further application in treating cancer.
13 cl, 16 ex, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS | 2014 |
|
RU2702428C2 |
| NOVEL PROTEIN STRUCTURES FOR DIAGNOSING AND THERAPY OF GD2-POSITIVE DISEASES | 2019 |
|
RU2708136C1 |
| METHOD FOR AMPLIFICATION OF NUCLEIC ACIDS OF HEAVY AND LIGHT CHAINS OF HUMAN IMMUNOGLOBULINS FOR THE CREATION OF RECOMBINANT ANTIBODIES, PRIMER COMPOSITIONS (VARIANTS) | 2020 |
|
RU2775914C2 |
| QUICK METHOD OF CLONING AND EXPRESSION OF RELATED ANTIBODY VARIABLE REGION GENE SEGMENTS | 2012 |
|
RU2612910C2 |
| VASCULAR ADHESIVE MOLECULES AND MODULATION OF THEIR FUNCTIONS | 2000 |
|
RU2244748C2 |
| MONOCLONAL ANTIBODY, NUCLEIC ACID AND VECTOR ENCODING ANTIBODY AND USING ANTIBODY FOR DIAGNOSIS AND TREATMENT OF MALIGNANT DISEASE | 1999 |
|
RU2235131C2 |
| ANTIBODY AGAINST PD-L1 | 2017 |
|
RU2744862C2 |
| RECONSTRUCTED HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN-8 | 1995 |
|
RU2159776C2 |
| RECOMBINANT PLASMID DNA, ENCODING HUMAN FACTOR VII PROTEIN SEQUENCE, CELL LINE BHK/F7, TRANSFORMED WITH PLASMID DNA | 2006 |
|
RU2337965C2 |
| CHIMERIC ANTIBODIES FOR TREATMENT OF DISEASES CHARACTERIZED BY AMYLOIDE DEPOSITION | 2018 |
|
RU2746325C1 |
